Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Anne S. Tsao, O. Wolf Lindwasser, Alex A. Adjei, Prasad S. Adusumilli, Matthew L. Beyers, Gideon M. Blumenthal, Raphael Bueno, Bryan M. Burt, Michele Carbone, Suzanne E. Dahlberg, Marc de Perrot, Dean A. Fennell, Joseph Friedberg, Ritu R. Gill, Daniel R. Gomez, David H. Harpole, Raffit Hassan, Mary Hesdorffer, Fred R. Hirsch, Julija HmeljakHedy L. Kindler, Edward L. Korn, Geoffrey Liu, Aaron S. Mansfield, Anna K. Nowak, Harvey I. Pass, Tobias Peikert, Andreas Rimner, Bruce W.S. Robinson, Kenneth E. Rosenzweig, Valerie W. Rusch, Ravi Salgia, Boris Sepesi, Charles B. Simone, Rajeshwari Sridhara, Peter Szlosarek, Emanuela Taioli, Ming Sound Tsao, Haining Yang, Marjorie G. Zauderer, Shakun M. Malik

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

On March 28– 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI–International Association for the Study of Lung Cancer– Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.

Original languageEnglish (US)
Pages (from-to)1655-1667
Number of pages13
JournalJournal of Thoracic Oncology
Volume13
Issue number11
DOIs
StatePublished - Nov 2018

Keywords

  • Clinical trials
  • Malignant mesothelioma
  • Multimodality therapy
  • Pleural
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation'. Together they form a unique fingerprint.

  • Cite this

    Tsao, A. S., Lindwasser, O. W., Adjei, A. A., Adusumilli, P. S., Beyers, M. L., Blumenthal, G. M., Bueno, R., Burt, B. M., Carbone, M., Dahlberg, S. E., de Perrot, M., Fennell, D. A., Friedberg, J., Gill, R. R., Gomez, D. R., Harpole, D. H., Hassan, R., Hesdorffer, M., Hirsch, F. R., ... Malik, S. M. (2018). Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology, 13(11), 1655-1667. https://doi.org/10.1016/j.jtho.2018.08.2036